Janssen Biotech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN BIOTECH, and when can generic versions of JANSSEN BIOTECH drugs launch?
JANSSEN BIOTECH has four approved drugs.
There are twenty-four US patents protecting JANSSEN BIOTECH drugs.
There are six hundred and thirty-nine patent family members on JANSSEN BIOTECH drugs in fifty-nine countries and seventy-three supplementary protection certificates in twenty countries.
Summary for Janssen Biotech
International Patents: | 639 |
US Patents: | 24 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 4 |
Patent Litigation for Janssen Biotech: | See patent lawsuits for Janssen Biotech |
Drugs and US Patents for Janssen Biotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | 11,673,877 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | 9,464,071 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | 8,143,241 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | 11,077,106 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | 10,849,888 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-002 | Apr 14, 2017 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Biotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-001 | Apr 28, 2011 | 5,604,213 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN BIOTECH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
International Patents for Janssen Biotech Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 3058375 | ⤷ Try a Trial |
China | 109908114 | ⤷ Try a Trial |
Costa Rica | 20140549 | ⤷ Try a Trial |
Hong Kong | 1212221 | ⤷ Try a Trial |
Costa Rica | 10910 | ⤷ Try a Trial |
Australia | 2022291429 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Biotech Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1633724 | PA2015016,C1633724 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
2368550 | 300993 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: APALUTAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1342 20190116 |
2109608 | 300937 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: NIRAPARIB, OF EEN TAUTOMEER DAARVAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET TOSYLAAT OF EEN HYDRAAT, MEER IN HET BIJZONDER HET TOSYLAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/17/1235 20171120 |
2240466 | 122018000052 | Germany | ⤷ Try a Trial | PRODUCT NAME: NIRAPARIBTOSYLAT, EINSCHLIESSLICH NIRAPARIBTOSYLATMONOHYDRAT; REGISTRATION NO/DATE: EU/1/17/1235 20171116 |
1633724 | 1590019-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218 |
2368550 | 132019000000084 | Italy | ⤷ Try a Trial | PRODUCT NAME: APALUTAMIDE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ERLEADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1342, 20190116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.